journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/28645631/outcomes-of-first-generation-egfr-tkis-against-non-small-cell-lung-cancer-harboring-uncommon-egfr-mutations-a-post-hoc-analysis-of-the-be-positive-study
#1
Sara Pilotto, Antonio Rossi, Tiziana Vavalà, Alessandro Follador, Marcello Tiseo, Domenico Galetta, Alessandro Morabito, Massimo Di Maio, Olga Martelli, Orazio Caffo, Pier Luigi Piovano, Diego Cortinovis, Nicoletta Zilembo, Clelia Casartelli, Giuseppe Luigi Banna, Antonio Ardizzoia, Maria Luisa Barzelloni, Alessandra Bearz, Giovenzio Genestreti, Claudia Mucciarini, Virginio Filipazzi, Jessica Menis, Elisa Rizzo, Fausto Barbieri, Erika Rijavec, Fabiana Cecere, Gianluca Spitaleri, Emilio Bria, Silvia Novello
BACKGROUND: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a "real-life" Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations...
June 1, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28645632/adjuvant-chemotherapy-guided-by-molecular-profiling-and-improved-outcomes-in-early-stage-non-small-cell-lung-cancer
#2
Gavitt A Woodard, Sue X Wang, Johannes R Kratz, Clara T Zoon-Besselink, Chun-Yuan Chiang, Matthew A Gubens, Thierry M Jahan, Collin M Blakely, Kirk D Jones, Michael J Mann, David M Jablons
INTRODUCTION: Many early stage non-small-cell lung cancer (NSCLC) patients who are not considered candidates for adjuvant treatment according to current guidelines do harbor occult metastasis, and have disease recurrence despite complete resection. Although National Comprehensive Cancer Network (NCCN) guidelines suggest clinicopathologic characteristics to identify high-risk patients for adjuvant intervention, molecular profiling more accurately predicts 5-year survival. Early evidence of clinical benefit from application of this molecular-based management strategy, however, has not been reported...
May 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28623122/a-randomized-phase-ii-study-comparing-nivolumab-with-carboplatin-pemetrexed-for-patients-with-egfr-mutation-positive-nonsquamous-non-small-cell-lung-cancer-who-acquire-resistance-to-tyrosine-kinase-inhibitors-not-due-to-a-secondary-t790m-mutation-rationale
#3
Hidetoshi Hayashi, Yasutaka Chiba, Kazuko Sakai, Tomonobu Fujita, Hiroshige Yoshioka, Daisuke Sakai, Chiyoe Kitagawa, Tateaki Naito, Koji Takeda, Isamu Okamoto, Tetsuya Mitsudomi, Yutaka Kawakami, Kazuto Nishio, Shinichiro Nakamura, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Antibodies to programmed cell death-1 (PD-1), such as nivolumab, have shown promising clinical activity in patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy appears to be less pronounced in patients with such tumors harboring epidermal growth factor receptor gene (EGFR) mutations. Recent findings suggest that patients with EGFR mutation-positive NSCLC who develop resistance to tyrosine kinase inhibitors (TKIs) due to mechanisms other than acquisition of the secondary T790M mutation of EGFR are more likely to benefit from nivolumab treatment, possibly as a result of a higher level of expression of the PD-1 ligand PD-L1, than are patients who are T790M-positive...
May 25, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28623121/radiomics-based-assessment-of-radiation-induced-lung-injury-after-stereotactic-body-radiotherapy
#4
Angel Moran, Megan E Daly, Stephen S F Yip, Tokihiro Yamamoto
BACKGROUND: Over 50% of patients who receive stereotactic body radiotherapy (SBRT) develop radiographic evidence of radiation-induced lung injury. Radiomics is an emerging approach that extracts quantitative features from image data, which may provide greater value and a better understanding of pulmonary toxicity than conventional approaches. We aimed to investigate the potential of computed tomography-based radiomics in characterizing post-SBRT lung injury. METHODS: A total of 48 diagnostic thoracic computed tomography scans (acquired prior to SBRT and at 3, 6, and 9 months post-SBRT) from 14 patients were analyzed...
May 25, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28601386/detection-of-alk-and-kras-mutations-in-circulating-tumor-dna-of-patients-with-advanced-alk-positive-nsclc-with-disease-progression-during-crizotinib-treatment
#5
Paola Bordi, Marcello Tiseo, Eleonora Rofi, Iacopo Petrini, Giuliana Restante, Romano Danesi, Marzia Del Re
BACKGROUND: In patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), disease progression occurs after a median of 9 to 10 months of crizotinib treatment. Several mechanisms of resistance have been identified and include ALK mutations and amplification or the activation of bypassing signaling pathways. Rebiopsy in NSCLC patients represents a critical issue and the analysis of circulating cell-free DNA (cfDNA) has a promising role for the identification of resistance mechanisms...
May 18, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28576593/impact-of-omission-of-intrapulmonary-lymph-node-retrieval-on-outcome-evaluation-of-lung-cancer-patients-without-lymph-node-metastasis-a-propensity-score-matching-analysis
#6
Xing Wang, Shi Yan, Chao Lv, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu
INTRODUCTION: Clinical practice of retrieval of segmental (station 13) and subsegmental (station 14) lymph nodes for pathologic examination varies during lung cancer surgery. This study aimed to evaluate whether omitting retrieval of nodes from stations 13 and 14 could affect outcome evaluation for patients with pN0 non-small-cell lung cancer (NSCLC). METHODS: This retrospective study analyzed 442 patients with NSCLC who were treated with both R0 resection and systematic mediastinal lymphadenectomy with pathologically confirmed stage pN0 NSCLC...
May 11, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28601388/a-randomized-placebo-controlled-phase-1b-2-study-of-rilotumumab-or-ganitumab-in-combination-with-platinum-based-chemotherapy-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer
#7
Bonnie Glisson, Benjamin Besse, Manuel Cobo Dols, Sarita Dubey, Marco Schupp, Rajul Jain, Yizhou Jiang, Hari Menon, Kristiaan Nackaerts, Sergey Orlov, Luis Paz-Ares, Rodryg Ramlau, Rui Tang, Yilong Zhang, Min Zhu
INTRODUCTION/BACKGROUND: In this randomized, double-blind, placebo-controlled phase 1b/2 study we assessed the efficacy/safety of rilotumumab or ganitumab combined with etoposide and carboplatin or cisplatin as first-line treatment in patients with extensive stage small-cell lung cancer (ES-SCLC). PATIENTS AND METHODS: In the phase 1b study, patients received rilotumumab 15 mg/kg or ganitumab 18 mg/kg with etoposide and carboplatin or cisplatin. In the phase 2 study, patients were randomly assigned 1:1:1 to receive placebo, rilotumumab, or ganitumab with etoposide and carboplatin or cisplatin...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28596108/association-between-egfr-t790m-status-and-progression-patterns-during-initial-egfr-tki-treatment-in-patients-harboring-egfr-mutation
#8
Yuko Oya, Tatsuya Yoshida, Hiroaki Kuroda, Junichi Shimizu, Yoshitsugu Horio, Yukinori Sakao, Yoshitaka Inaba, Toyoaki Hida, Yasushi Yatabe
BACKGROUND: Emergence of the T790M point mutation in exon 20 of the epidermal growth factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study was to investigate the association between T790M mutation status and the progression patterns during EGFR-TKI treatment. METHODS: We reviewed 181 patients with advanced non-small-cell lung cancer harboring EGFR mutation, who were evaluated for T790M mutation status after initial EGFR-TKI failure (gefitinib, erlotinib, or afatinib)...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28583380/comparison-of-radiotherapy-and-chemoradiotherapy-for-locoregional-recurrence-of-non-small-cell-lung-cancer-developing-after-surgery
#9
Shinji Nakamichi, Hidehito Horinouchi, Tetsuhiko Asao, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yoshinori Ito, Shun-Ichi Watanabe, Yuichiro Ohe
BACKGROUND: The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is yet to be clearly established. PATIENTS AND METHODS: To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the consecutive data of patients with NSCLC with postoperative locoregional recurrences treated at the National Cancer Center Hospital between January 2000 and April 2010...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28583379/prognostic-role-of-the-fgfr4-388arg-variant-in-lung-squamous-cell-carcinoma-patients-with-lymph-node-involvement
#10
Álvaro Quintanal-Villalonga, Andrés Carranza-Carranza, Ricardo Meléndez, Irene Ferrer, Sonia Molina-Pinelo, Luis Paz-Ares
BACKGROUND: The identification of prognostic biomarkers for lung squamous-cell carcinoma (SCC) pathology is crucial because of its poor prognosis. A variant of the FGFR4 (fibroblast growth factor receptor 4) gene, FGFR4-388Arg, has been associated with prognosis and is linked to oncogenesis in vitro in several types of cancer. We analyzed the association of this variant with prognosis and downstream signaling alteration in lung SCC patients. METHODS: The presence of the FGFR4-388Arg variant was determined in 114 formalin-fixed, paraffin-embedded lung SCC tissue samples by DNA genotyping and was correlated with clinicopathologic data...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28579188/effects-of-histamine-2-receptor-antagonists-and-proton-pump-inhibitors-on-the-pharmacokinetics-of-gefitinib-in-patients-with-non-small-cell-lung-cancer
#11
Hayato Yokota, Kazuhiro Sato, Yuji Okuda, Hiroyuki Kobayashi, Masahide Takeda, Mariko Asano, Hiroshi Ito, Masatomo Miura
INTRODUCTION: In this study, we investigated the degree of drug interactions between gefitinib and gastric acid suppressants (ie, histamine 2-receptor antagonists [H2RAs] or proton pump inhibitors [PPIs]) with a clinical standard dose in Japanese patients with non-small-cell lung cancer. METHODS: Retrospectively, 47 patients were divided into 3 groups: gefitinib therapy with a PPI (15 patients) or an H2RA (8 patients) or gefitinib therapy alone (24 patients). On day 15 after beginning gefitinib therapy (administration at 08:00) with or without H2RA (administration twice daily at 08:00 and 18:30) or PPI (administration once daily at 08:00 or 18:30), whole blood samples were collected just prior to and at 1, 2, 4, 6, 8, 12, and 24 hours after administration...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28576595/prognostic-impact-of-minimal-pericardial-effusion-in-patients-with-advanced-non-small-cell-lung%C3%A2-cancer
#12
Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
INTRODUCTION: Minimal (< 10 mm in thickness) pericardial effusion (PCE) can be incidentally detected by computed tomography at the time of diagnosis in patients with lung cancer. Although malignant PCE is known to be associated with poor prognosis, the impact of minimal PCE on outcome has remained unclear. We therefore examined the prognostic relevance of minimal PCE in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We retrospectively analyzed consecutive patients diagnosed with stage IV NSCLC at Kindai University Hospital between April 2009 and March 2015...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28576592/evaluating-the-genomic-yield-of-a-single-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-in-lung-cancer-meeting-the-challenge-of-doing-more-with-less
#13
Tracy L Leong, Michael Christie, Sevastjan Kranz, Kym Pham, Arthur Hsu, Louis B Irving, Marie-Liesse Asselin-Labat, Daniel P Steinfort
BACKGROUND: Minimally invasive techniques, including endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), yield small specimens that are adequate for cytologic diagnosis of lung cancer, but also need to provide material for molecular analysis to guide treatment. The number of EBUS-TBNA passes needed for mutation testing remains unclear. We sought to assess the adequacy of a single pass for genomic profiling of actionable mutations. METHODS: In a prospective observational study, paired samples from the same lesion were obtained from patients undergoing EBUS-TBNA for lung cancer diagnosis/staging...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28571689/consequences-of-referral-time-and-volume-doubling-time-in-inoperable-patients-with-early-stage-lung-cancer
#14
Michael Frelinghuysen, Jesse Fest, Noelle C Van der Voort Van Zyp, Bronno Van der Holt, Mischa Hoogeman, Joost Nuyttens
BACKGROUND: Inoperable patients with early stage lung cancer are referred late. The purpose was to calculate the referral time and the volume doubling time (VDT), and to investigate its consequence with regard to staging and survival in 117 inoperable patients with early stage lung cancer treated with stereotactic body radiotherapy. MATERIALS AND METHODS: Tumor VDT was calculated using the modified Schwartz formula of exponential growth model and was on the basis of volumes measured on initial diagnostic computed tomography (CT) scans and the planning CT scan...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28559200/external-validation-of-the-new-international-association-for-the-study-of-lung-cancer-tumor-node-and-metastasis-8th-edition-staging-system-and-updated-t-descriptors-in-determining-prognosis-for-patients-with-non-small-cell-lung-cancer-patients-with-n3-disease
#15
Jacob Y Shin, Ja Kyoung Yoon, Gaurav Marwaha
OBJECTIVE: The objective of this study is to externally validate the 8th Edition of the Tumor, Node, and Metastasis staging system and its updated T descriptors in patients with non-small cell lung cancer with N3 disease. METHODS: Data were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test, Kaplan-Meier method, and Cox regression models were used in SPSS 23.0 (IBM Corp, Armonk, NY). RESULTS: A total of 7732 patients with non-small cell lung cancer with T1-4N3M0 disease from 1988 to 2013 were identified...
May 10, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28576594/time-and-effort-required-for-tissue-acquisition-and-submission-in-lung-cancer-clinical-trials
#16
Sandra Garcia, Jessica M Saltarski, Jingsheng Yan, Xian-Jin Xie, David E Gerber
BACKGROUND: Increasingly, analysis of tumor tissue samples for predictive and pharmacodynamic biomarkers is incorporated into lung cancer clinical trials. We determined the time and effort required for tissue acquisition and submission. PATIENTS AND METHODS: We analyzed data from patients enrolled from 2009 to 2016 at UT Southwestern onto lung cancer trials with mandatory or optional submission of tumor tissue. We collected dates of treatment-related events and staff communications; nature of tissue requirement and biomarker analysis; and location of archival tissue...
May 8, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28549835/characterization-of-liver-metastasis-and-its-effect-on-targeted-therapy-in-egfr-mutant-nsclc-a-multicenter-study
#17
Tao Jiang, Ruirui Cheng, Guowei Zhang, Chunxia Su, Chao Zhao, Xuefei Li, Jie Zhang, Fegnying Wu, Xiaoxia Chen, Guanghui Gao, Wei Li, Weijing Cai, Fei Zhou, Jing Zhao, Anwen Xiong, Shengxiang Ren, Guojun Zhang, Caicun Zhou, Jun Zhang
BACKGROUND: The risk factors for liver metastasis (LM) in patients with non-small-cell lung cancer (NSCLC) remain unknown. Whether LM predicts for the effect of first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant NSCLC needs to be explored. PATIENTS AND METHODS: A total of 598 NSCLC patients from 3 centers underwent EGFR testing, and 293 had EGFR-mutant NSCLC. Of the 598 NSCLC patients, 99 had LM; 56 patients with EGFR-mutant NSCLC received EGFR-TKIs as first-line therapy...
May 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28549836/heterogeneity-of-tumor-and-immune-cell-pd-l1-expression-and-lymphocyte-counts-in-surgical-nsclc-samples
#18
David Casadevall, Sergi Clavé, Álvaro Taus, Max Hardy-Werbin, Pedro Rocha, Marta Lorenzo, Silvia Menéndez, Marta Salido, Joan Albanell, Lara Pijuan, Edurne Arriola
BACKGROUND: Immune-checkpoint inhibitors against programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have shown remarkable therapeutic activity in non-small-cell lung cancer (NSCLC). However, biomarker-based patient selection remains a challenge. Our aim was to assess the heterogeneity of various immune markers between different tumor areas of surgically resected NSCLC specimens. MATERIALS AND METHODS: We included 94 adenocarcinoma (ADC) and 50 squamous cell carcinoma (SCC) specimens...
May 4, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28601387/guideline-concordant-care-improves-overall-survival-for-locally-advanced-non-small-cell-lung-carcinoma-patients-a-national-cancer-database-analysis
#19
Hiba Z Ahmed, Yuan Liu, Kelli O'Connell, Maaz Z Ahmed, Richard J Cassidy, Theresa W Gillespie, Pretesh Patel, Rathi N Pillai, Madhusmita Behera, Conor E Steuer, Taofeek K Owonikoko, Suresh S Ramalingam, Walter J Curran, Kristin A Higgins
BACKGROUND: Current evidence-based guideline-concordant care (GCC) for locally advanced non-small-cell lung cancer (NSCLC) patients with good performance status is concurrent chemoradiation. In this study we evaluated factors associated with lack of GCC and its effects on overall survival (OS). PATIENTS AND METHODS: Unresectable stage III NSCLC patients, diagnosed from 2005 to 2013 with a Charlson-Deyo score of 0, were identified from the National Cancer Database...
April 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28550959/coexistence-of-egfr-kras-braf-and-pik3ca-mutations-and-alk-rearrangement-in-a%C3%A2-comprehensive-cohort-of-326-consecutive-spanish-nonsquamous-nsclc-patients
#20
Paloma Martín Martorell, Marisol Huerta, Amparo Compañ Quilis, Rosario Abellán, Enrique Seda, Sebastián Blesa, Felipe J Chaves, Diego Dualde Beltrán, Susana Roselló Keränen, José Franco, Amelia Insa
INTRODUCTION: Molecular screening is crucial for the care of nonsquamous non-small-cell lung cancer (NSCLC) patients. The coexistence of mutations could have important consequences regarding treatment. We described the mutational patterns and coexistence among patients and their outcomes after targeted treatment. MATERIALS AND METHODS: Data from consecutive patients with newly diagnosed nonsquamous NSCLC were prospectively collected. Next-generation sequencing analysis of mutational hotspots in the EGFR, KRAS, PIK3CA, and BRAF genes and analysis of anaplastic lymphoma kinase (ALK) rearrangement were performed...
April 27, 2017: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"